GlassScriptPhysician profile
John P Dodaro
NPI 1407817562
$3,834.86
in general payments reported to CMS, 2019-2025
27 companies · $947 in 2025
The $947 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $246 · 2021: $314 · 2022: $489 · 2023: $697 · 2024: $824 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.92 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $739.47 | 2020-2025 | |
| Genzyme Corporation | $466.24 | 2021-2025 | |
| Aerin Medical INC. | $434.60 | 2024-2025 | |
| Glaxosmithkline, LLC. | $352.69 | 2019-2025 | Nucala |
| Stryker Corporation | $279.08 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $275.26 | 2020-2025 | Dupixent |
| Csl Behring | $195.96 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Alk-Abello, INC | $136.30 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Oyster Point Pharma, INC. | $121.89 | 2022 | |
| Medtronic, INC. | $118.06 | 2025 | Propel, Nuvent |
| Kaleo, INC. | $117.66 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $87.03 | 2020-2025 | Cuvitru, Eohilia |
| Integra Lifesciences Corporation | $80.18 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Sanofi-Aventis U.S. LLC | $74.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $64.29 | 2023-2025 | Fasenra, Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $50.20 | 2019-2023 | Panzyga |
| Grifols USA, LLC | $47.34 | 2024-2025 | Xembify |
| Merck Sharp & Dohme LLC | $31.09 | 2023 | |
| Hikma Pharmaceuticals USA | $30.14 | 2022-2025 | Ryaltris |
| Smith+Nephew, INC. | $30.02 | 2020-2025 | Tula |
| Paratek Pharmaceuticals, INC. | $23.26 | 2025 | Xhance |
| Acclarent, INC | $16.64 | 2019 | |
| Shire North American Group INC | $13.56 | 2019 | |
| Leo Pharma INC. | $12.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.62 | 2021 | |
| Incyte Corporation | $12.11 | 2022 | |
| Bio Products Laboratory USA, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dodaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.